(Q33637687)

28 July 2017

1 reference

title

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease (English)

1 reference

28 July 2017

0 references

W J Krall

1

1 reference

28 July 2017

J J Sramek

series ordinal

2

1 reference

28 July 2017

N R Cutler

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

Annals of Pharmacotherapy

28 July 2017

1 reference

28 July 2017

33

1 reference

28 July 2017

441-450

1 reference

28 July 2017

4

1 reference

The cholinergic hypothesis of geriatric memory dysfunction

28 July 2017

1 reference

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

21 January 2018

1 reference

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

21 January 2018

1 reference

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

21 January 2018

1 reference

Cognitive enhancement therapy for Alzheimer's disease. The way forward

21 January 2018

1 reference

Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease

21 January 2018

1 reference

Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease

21 January 2018

1 reference

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

21 January 2018

1 reference

Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor

21 January 2018

1 reference

The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex

21 January 2018

1 reference

Asymmetric and globular forms of acetylcholinesterase in mammals and birds

21 January 2018

1 reference

Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain.

21 January 2018

1 reference

A monoclonal antibody assay technique for plasma and red cell acetylcholinesterase activity in Alzheimer's disease

21 January 2018

1 reference

Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: Effects of concurrent administration of physostigmine and methylphenidate with scopolamine

21 January 2018

1 reference

Oral physostigmine treatment of patients with Alzheimer's disease.

21 January 2018

1 reference

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

21 January 2018

1 reference

Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease

21 January 2018

1 reference

A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.

21 January 2018

1 reference

Evaluation of HP 029 (Velnacrine Maleate) in Alzheimer's Diseasea

21 January 2018

1 reference

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study

21 January 2018

1 reference

The bridging concept: optimizing dose for phase II/III in Alzheimer's disease

21 January 2018

1 reference

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.

21 January 2018

1 reference

Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.

21 January 2018

1 reference

Regulation of hippocampal 5-HT1A receptor gene expression by dexamethasone.

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

21 January 2018

1 reference

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

21 January 2018

1 reference

21 January 2018

1 reference

Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease

21 January 2018

1 reference

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

21 January 2018

1 reference

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

21 January 2018

1 reference

Donepezil use in Alzheimer disease

21 January 2018

1 reference

21 January 2018

1 reference

Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds

21 January 2018

1 reference

Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase.

21 January 2018

1 reference

Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-(2-phthalimidoethyl)piperidine and related derivatives

21 January 2018

1 reference

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease

21 January 2018

1 reference

Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients.

21 January 2018

1 reference

Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease.

21 January 2018

1 reference

Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.

21 January 2018

1 reference

Effects of oral physostigmine in Alzheimer's disease.

21 January 2018

1 reference

Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor

21 January 2018

1 reference

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

21 January 2018

1 reference

21 January 2018

1 reference

Mechanism of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of O,O-dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate (trichlorphon)

21 January 2018

1 reference

Transformation and action of metrifonate.

21 January 2018

1 reference

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

21 January 2018

1 reference

Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study

21 January 2018

1 reference

Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?

21 January 2018

1 reference

Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man.

21 January 2018

1 reference

The pharmacology of galanthamine and its analogues

21 January 2018

1 reference

21 January 2018

1 reference

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

21 January 2018

1 reference

Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients

21 January 2018

1 reference

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

21 January 2018

1 reference

A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

21 January 2018

1 reference

Emerging antidementia drugs: a preliminary ethical view.

21 January 2018

1 reference

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.18211

1 reference

release_au4iusl2xfc53fytnfazqggq4e

28 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/au4iusl2xfc53fytnfazqggq4e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference